Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The company has operations in Europe, Singapore, and the United States of America. The company develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.
Follow-Up Questions
Clinuvel Pharmaceuticals Ltd 的 CEO 是誰？
Dr. Philippe Wolgen 是 Clinuvel Pharmaceuticals Ltd 的 Chief Executive Officer，自 2005 加入公司。
CLVLY 股票的價格表現如何？
CLVLY 的當前價格為 $7.92，在上個交易日 decreased 了 0%。
Clinuvel Pharmaceuticals Ltd 的主要業務主題或行業是什麼？
Clinuvel Pharmaceuticals Ltd 屬於 Biotechnology 行業，該板塊是 Health Care
